Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fulcrum Therapeutics Buyback Yield % Related Terms
Fulcrum Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Fulcrum Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FULC vs AGEN, IRD, TTRX: Buyback Yield % Comparison
For the Biotechnology subindustry, Fulcrum Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulcrum Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fulcrum Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Fulcrum Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fulcrum Therapeutics (FULC) has a Buyback Yield % of 0.00 as of Aug. 13, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Fulcrum Therapeutics and its competitors. According to the industry distribution chart, Fulcrum Therapeutics ranks #999999 out of 725 companies in the Biotechnology industry.
Is Fulcrum Therapeutics' Buyback Yield % too high?
Fulcrum Therapeutics' current Buyback Yield % is 0.00. Based on the distribution chart, Fulcrum Therapeutics ranks #999999 out of 725 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Fulcrum Therapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Fulcrum Therapeutics' Buyback Yield % compare to AGEN and IRD?
According to the Biotechnology industry distribution chart, Fulcrum Therapeutics ranks #999999 out of 725 companies for Buyback Yield %. This places Fulcrum Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Fulcrum Therapeutics and its competitors. Fulcrum Therapeutics's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulcrum Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Fulcrum Therapeutics (FULC) is currently considered Possible Value Trap. The stock's GF Value™ is $32.03, compared to a current price of $3.73 — trading 88.4% below its estimated fair value. The current Buyback Yield % is 0.00. Fulcrum Therapeutics' overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Fulcrum Therapeutics (FULC), the current Buyback Yield % is 0.00 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fulcrum Therapeutics (FULC) Overvalued in 2026?
Based on GuruFocus' analysis, Fulcrum Therapeutics stock appears to be undervalued.
The current stock price of $3.73 is trading 88.4% below its estimated GF Value™ of $32.03.
GuruFocus considers Fulcrum Therapeutics to be Possible Value Trap.
Key valuation signals for FULC:
Buyback Yield %: 0.00
GF Value™: $32.03 vs. price of $3.73 (88.4% below fair value)
No single metric tells the full story. See the FULC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
44GF Score
Get the complete analysis for FULC
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FULC has been successfully added to your 
